Abstract
Process automation, CIM and paperless manufacturing are operational strategies being developed to support the changing business strategies in pharmaceuticals. Present FDA activities appear to make automation an attainable GMP regulatory reality. Operations are being required to provide greater benefits in the form of efficiencies, manpower rationalization, and productivity gains in order to justify new CIM and automation projects. This paper describes where benefits have been identified and quantified in operational environments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
